Sydney Lepkin

Instead, the company developed a new ingredient, Orfaglipron.

Daniel Skowronski, the company's chief scientific and medical officer, says until now, all of these GLP-1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions.

Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month, and for people paying cash, the lowest dose will cost $149 a month.

Sydney Lepkin, NPR News.

You're listening to NPR.

Novo Nordisk will drop its lawsuit against HIMSS.

In exchange, HIMSS will stop advertising its compounded version of Novo Nordisk's Wagovi.

Compounded drugs are made by a specialized pharmacy, not a drug company.

HIMS will continue to offer compounded semaglutide, the active ingredient in Wagovi, but on a more limited scale, it says.

It will also offer brand-name Wagovi injections and pills on its telehealth platform starting later this month.

HIMS launched a compounded version of Novo Nordisk's brand-new weight loss pill in February.

After Novo threatened to sue and federal regulators signaled a crackdown, HIMS said it would drop its copycat pill.

Novo Nordisk then sued him for patent infringement and now has withdrawn that suit.

Sydney Lepkin, NPR News.

The Danish drug company Novo Nordisk now charges more than $1,000 a month for its blockbuster drugs Ozempic and Wegovy.

That's the list price, the one that plays a role in which drugs insurers choose to cover and what the patient ultimately pays out of pocket at the pharmacy counter.

Starting in 2027, the list price for the drugs will drop to $675 for a month's supply.

That's also when lower negotiated prices for Medicare kick in.

The company already offers discounts for patients paying cash.

but those prices aren't changing for now.